Medicenna Therapeutics Corp (MDNA.TO) experienced a notable drop in its stock price, closing down 3.85% in the latest trading session.
On a challenging trading day, Medicenna's stock closed at CA$0.38, reflecting a decline of 3.85%. This downturn occurs amid ongoing market volatility and cautious investor sentiment.
Investor takeaway: Investors should be cautious of potential volatility in biotech stocks like Medicenna, especially considering recent public offerings and the current market mood.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$33.23M
52W high
$1.97
52W low
$0.34
1W change
+2.86%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 788.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+788.9% Upside
Current Price
C$0.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
34.7%
Annualized
90-Day Vol
67.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.30
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.30 – C$0.38 |
| 60 trading days | C$0.32 | C$0.27 – C$0.38 |
| 90 trading days | C$0.30 | C$0.24 – C$0.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Bull case
Despite today’s decline, Medicenna is making progress in its drug development pipeline. If clinical trials produce positive results, this could lead to future growth for the company.
Bear case
The recent public offerings and the stock's performance raise concerns about dilution and investor confidence. This is particularly relevant in a sector known for its unpredictability.
Market Reaction to Medicenna's Stock Performance
Advertisement
The 3.85% drop in Medicenna's stock today reflects broader market concerns regarding biotech investments. Investors are especially cautious following the company's recent public offerings, which could affect share value and overall market confidence.
What This Means for Investors
For those invested in Medicenna, today’s performance serves as a reminder of the risks inherent in the biotech sector. As the company continues to work on its drug development goals, investors should stay alert and consider the potential implications of dilution from public offerings. For more details on Medicenna's stock performance, visit MDNA.TO.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
